Current Vascular Pharmacology
Title:Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?)
Volume: 10 Issue: 3
Author(s): Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis and Dimitri P. Mikhailidis
Affiliation:
Keywords: Chronic kidney disease, coronary heart disease equivalent, guidelines, statins, dyslipidaemia
Export Options
About this article
Cite this article as:
G. Athyros Vasilios, Katsiki Niki, Karagiannis Asterios and P. Mikhailidis Dimitri, Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?), Current Vascular Pharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157016112799959422
DOI https://dx.doi.org/10.2174/157016112799959422 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidemiology of Diabetes Mellitus in the United Arab Emirates
Current Diabetes Reviews Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology Ibogaine in the Treatment of Substance Dependence
Current Drug Abuse Reviews Magnesium as a Neuroprotective Agent in Cerebral Ischemia
Current Medicinal Chemistry - Central Nervous System Agents Pathogenesis and Immune Status in COVID-19 Pneumonia - A Minireview
Coronaviruses Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) Extracellular Matrix Scaffolds for Tissue Engineering and Regenerative Medicine
Current Stem Cell Research & Therapy Orthostatic Hypotension: Evaluation and Treatment
Cardiovascular & Hematological Disorders-Drug Targets Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome
Current Drug Metabolism Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Thoughtful Insights into the Therapeutic Armamentarium of Chalcones: 10 Years of Glorious Journey
Current Bioactive Compounds Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Current Pharmaceutical Biotechnology Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) BACE1 Structure and Function in Health and Alzheimers Disease
Current Alzheimer Research MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Patenting of Nanopharmaceuticals in Drug Delivery: No Small Issue
Recent Patents on Drug Delivery & Formulation A Role for Rev-erbα Ligands in the Regulation of Adipogenesis
Current Pharmaceutical Design